Cefazolin versus anti-staphylococcal penicillins for treatment of methicillin-susceptible Staphylococcus aureus bacteraemia: a narrative review
Paul Loubet (1), Charles Burdet (1,2), William Vindrios, Nathalie, Grall (1), Michel Wolff, Yazdan Yazdanpanah (1), Antoine Andremont (1),, Xavier Duval (1), Fran\c{c}ois-Xavier Lescure (1) ((1) IAME, (2) DEBRC)
TL;DR
This narrative review compares the effectiveness and safety of cefazolin and anti-staphylococcal penicillins in treating MSSA bacteraemia, addressing clinical, safety, and ecological concerns.
Contribution
It synthesizes current evidence to clarify the comparative efficacy and safety profiles of cefazolin versus ASPs for MSSA bacteraemia.
Findings
Cefazolin shows comparable efficacy to ASPs in MSSA bacteraemia.
Safety profiles differ, with cefazolin potentially having fewer adverse effects.
Uncertainty remains regarding cefazolin's efficacy in deep infections.
Abstract
Anti-staphylococcal penicillins (ASPs) are recommended as first-line agents in methicillin-susceptible Staphylococcus aureus (MSSA) bacteraemia. Concerns about their safety profile have contributed to the increased use of cefazolin. The comparative clinical effectiveness and safety profile of cefazolin versus ASPs for such infections remain unclear. Furthermore, uncertainty persists concerning the use of cefazolin due to controversies over its efficacy in deep MSSA infections and its possible negative ecological impact.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.